212 related articles for article (PubMed ID: 33283314)
1. Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: A review of the literature.
El Kawkgi OM; Ross DS; Stan MN
Clin Endocrinol (Oxf); 2021 Jul; 95(1):3-12. PubMed ID: 33283314
[TBL] [Abstract][Full Text] [Related]
2. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
3. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
4. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
Fung MHM; Lang BHH
Eur Radiol; 2023 Sep; 33(9):6534-6544. PubMed ID: 37036479
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study.
Brito JP; Payne S; Singh Ospina N; Rodriguez-Gutierrez R; Maraka S; Sangaralingham LR; Iñiguez-Ariza NM; Montori VM; Stan MN
Thyroid; 2020 Mar; 30(3):357-364. PubMed ID: 31973681
[No Abstract] [Full Text] [Related]
7. Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves' Disease.
Kim MJ; Cho SW; Kim YA; Choi HS; Park YJ; Park DJ; Cho BY
Endocrinol Metab (Seoul); 2022 Jun; 37(3):524-532. PubMed ID: 35709827
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
9. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.
Vigone MC; Peroni E; Di Frenna M; Mora S; Barera G; Weber G
J Endocrinol Invest; 2020 May; 43(5):595-600. PubMed ID: 31713721
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities.
Hegedüs L
Endocrinol Metab Clin North Am; 2009 Jun; 38(2):355-71, ix. PubMed ID: 19328416
[TBL] [Abstract][Full Text] [Related]
11. Definitive treatment of Graves' disease in children and adolescents.
Król A; Czarniecka A; Jarząb B
Endokrynol Pol; 2021; 72(6):661-665. PubMed ID: 34855196
[TBL] [Abstract][Full Text] [Related]
12. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
[TBL] [Abstract][Full Text] [Related]
13. The tale of radioiodine and Graves' orbitopathy.
Ponto KA; Zang S; Kahaly GJ
Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
[TBL] [Abstract][Full Text] [Related]
14. Long-term thionamide antithyroid treatment of Graves' disease.
Azizi F; Abdi H; Amouzegar A; Habibi Moeini AS
Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101631. PubMed ID: 35440398
[TBL] [Abstract][Full Text] [Related]
15. Impaired immune regulation after radioiodine therapy for Graves' disease and the protective effect of Methimazole.
Côté-Bigras S; Tran V; Turcotte S; Rola-Pleszczynski M; Verreault J; Rottembourg D
Endocrine; 2016 Jun; 52(3):587-96. PubMed ID: 26701678
[TBL] [Abstract][Full Text] [Related]
16. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
18. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed Graves' disease.
Liu X; Wong CKH; Chan WWL; Tang EHM; Woo YC; Liu SYW; Lam CLK; Lang BHH
Br J Surg; 2022 Mar; 109(4):381-389. PubMed ID: 35136950
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Graves' Disease Patients Following Antithyroid Drugs, Radioactive Iodine, or Thyroidectomy as the First-line Treatment.
Liu X; Wong CKH; Chan WWL; Tang EHM; Woo YC; Lam CLK; Lang BHH
Ann Surg; 2021 Jun; 273(6):1197-1206. PubMed ID: 33914484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
